ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Apr 2022
Last Updated on 02 Jan 2024

A- A+

Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended: Olaparib 100 mg and 150 mg tablets; and Niraparib 100 mg tablet for treating advanced ovarian cancer in line with specific clinical criteria.
Funding status
Olaparib 100 mg and 150 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) with effect from 1 September 2022 for the following indications: As maintenance monotherapy for adults with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Treatment should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months; In combination with bevacizumab biosimilar (subsidised brand) as maintenance treatment of adults with advanced homologous recombination deficiency (HRD) positive high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab biosimilar. Treatment with olaparib should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months; and As maintenance monotherapy for patients with platinum-sensitive relapsed BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Patients must not have received prior treatment with a PARP inhibitor for ovarian cancer. Treatment should be continued until disease progression or unacceptable toxicity. Niraparib 100 mg tablet is recommended for inclusion on the MAF with effect from 1 March 2024 for the following indication: As maintenance monotherapy for patients with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with BRCA mutation and/or HRD-positive status. Treatment should be continued until disease progression or unacceptable toxicity or for a maximum of 36 months. Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

Olaparib 100 mg and 150 mg tablets; and
Niraparib 100 mg tablet

for treating advanced ovarian cancer in line with specific clinical criteria.

Funding status

Olaparib 100 mg and 150 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) with effect from 1 September 2022 for the following indications:

As maintenance monotherapy for adults with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Treatment should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months;
In combination with bevacizumab biosimilar (subsidised brand) as maintenance treatment of adults with advanced homologous recombination deficiency (HRD) positive high grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab biosimilar. Treatment with olaparib should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months; and
As maintenance monotherapy for patients with platinum-sensitive relapsed BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Patients must not have received prior treatment with a PARP inhibitor for ovarian cancer. Treatment should be continued until disease progression or unacceptable toxicity.

Niraparib 100 mg tablet is recommended for inclusion on the MAF with effect from 1 March 2024 for the following indication:

As maintenance monotherapy for patients with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with BRCA mutation and/or HRD-positive status. Treatment should be continued until disease progression or unacceptable toxicity or for a maximum of 36 months.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

PARP inhibitors and bevacizumab for treating advanced ovarian cancer (Updated 2 Jan 2024) PES Treatments for advanced ovarian cancer (Updated 2 Jan 2024)